Pharmaceutical

As pharmas play up their U.S. investment plans during the second Trump administration, the particulars of one project at AbbVie are coming into focus.

More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee to consider the asset’s...

Texas Attorney General Ken Paxton and Health Choice Alliance are accusing Eli Lilly of “incentivizing” providers in the state to prescribe its drugs,...

The startup agreed to pay Fosun Pharma as much as $645 million for a drug in testing for multiple lung conditions, including bronchiectasis.

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its study goal, while Biogen and...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for idiopathic pulmonary fibr...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis....

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indicatio...

Cold Chain Technologies is eliminating 82 positions at its headquarters in Franklin, Massachusetts, according to a state Worker Adjustment and Retrain...